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A B S T R A C T
Autism spectrum disorder (ASD) aﬀects over 1:100 of the population and costs the UK more than £32bn and the
USA more than $175bn (£104bn) annually. Its core symptoms are social and communication diﬃculties, re-
petitive behaviours and sensory hyper- or hypo-sensitivities. A highly diverse phenotypic presentation likely
reﬂects its etiological heterogeneity and makes ﬁnding treatment targets for ASD challenging. In addition, there
are no means to identify biologically responsive individuals who may beneﬁt from speciﬁc interventions. There
is hope however, and in this review we consolidate how ﬁndings from magnetic resonance spectroscopy (MRS)
add to the evidence that diﬀerences in the brain's excitatory glutamate and inhibitory γ-aminobutyric acid
(GABA) balance may be both a key biomarker and a tractable treatment target in ASD.
1. Introduction
Autism spectrum disorder (ASD) is a highly heterogeneous lifelong
neurodevelopmental syndrome characterised by deﬁcits in social re-
ciprocity and communication, and by restricted interests and stereo-
typed behaviours (DSM-5; American Psychiatric Association, 2013). Its
prevalence is growing (Lai et al., 2014) and, in the UK alone, adults
with ASD cost the economy over £32 billion/year, i.e. more than heart
disease, cancer and stroke combined (Buescher et al., 2014). Therefore,
there is a pressing need to identify the underlying biological mechan-
isms that would provide a basis for the development of ASD stratiﬁ-
cation markers and treatment options. Progress is happening however,
based on accumulating evidence that multiple genetic and environ-
mental risk factors for ASD converge to disrupt the balance between
glutamate-mediated excitatory and γ-aminobutyric acid (GABA)-medi-
ated inhibitory neurotransmission; and this may inform treatment tar-
gets for the disorder (Nelson and Valakh, 2015; Rubenstein and
Merzenich, 2003).
2. Evidence for excitation-inhibition imbalance in autism
spectrum disorder
A balanced interaction between glutamate and GABA is essential for
synaptic maturation, reﬁnement of neuronal circuitry and subsequently
the regulation of cognition, emotion and behaviour (Lujan et al., 2005).
An imbalance in excitation-inhibition (E-I) caused by disruption to any
component of the glutamate and GABA signalling systems could
therefore have potentially far-reaching consequences. Indeed, based on
observations such as an increased incidence of epilepsy – a disorder of
E-I balance – in individuals with ASD (Bolton et al., 2011; Muhle et al.,
2004), and post-mortem evidence of altered expression of proteins in-
volved in glutamate and GABA biosynthesis and neurotransmission in
the brains of individuals with ASD (Blatt and Fatemi, 2011; Fatemi
et al., 2002, 2009, 2014; Oblak et al., 2009, 2010, 2011; Purcell et al.,
2001; Shimmura et al., 2013; Yip et al., 2007), E-I imbalance has been
suggested to be a ‘common ﬁnal pathway’ in ASD (Nelson and Valakh,
2015; Rubenstein and Merzenich, 2003).
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Genetic studies are in line with this proposal. For example, studies
of ASD susceptibility genes have repeatedly identiﬁed chromosome
15q11-13 as a particular region of interest as 1–3% of all ASD cases
were reported to be associated with duplications in this region
(Moreno-De-Luca et al., 2013; Urraca et al., 2013). This chromosomal
region contains genes for three GABAA receptor subtype genes (i.e. β3,
γ3 and α5). Mutations in this region, especially in the β3 subunit,
convey a high risk for ASD and have been linked to repetitive symptoms
and insistence on sameness (Chaste et al., 2014; Isles et al., 2016; Shao
et al., 2003). Direct evidence for the link between GABAA-β3 and ASD
has also been generated from a β3 knock-out mouse. These mice have
behaviours analogous to the condition; they also have seizures, which
are a frequent comorbid complication of ASD caused by E-I imbalance
(DeLorey et al., 1998). In addition, we and others have reported that
environmental risk factors for ASD, such as prenatal exposure to ma-
ternal inﬂammation or the anti-epilepsy medication valproate, disrupt
gene and protein expression across GABA pathways and trigger beha-
vioural features which mimic the human condition (Fatemi et al., 2008;
Fukuchi et al., 2009; Giovanoli et al., 2014; Meyer et al., 2011; Wei
et al., 2016).
There is also good evidence for genetic abnormalities in glutama-
tergic signalling pathways in ASD and related conditions. This has, in
part, been built on the advances made in fragile X syndrome, the most
common genetic form of ASD, which is caused by a single gene muta-
tion aﬀecting fragile X mental retardation protein (FMRP) (Verkerk
et al., 1991). FMRP negatively regulates postsynaptic glutamate re-
ceptor synthesis (including metabotropic glutamate receptor 5;
mGluR5) by binding to ribosomes and stalling translation of target
mRNAs (Darnell et al., 2011). mRNA translation at the synapse is then
increased (Bear et al., 2004), leading to excess excitatory activity, en-
hanced long term depression, and ASD-like pathology in animal models
(Lozano et al., 2014; Yu and Berry-Kravis, 2014). Lower levels of FMRP
are found in individuals with idiopathic ASD (i.e. ASD without a known
cause) who have a concomitant increase in mGluR5 (Fatemi et al.,
2011; Fatemi and Folsom, 2011). In addition to alterations to meta-
botropic receptors in ASD, genetic aberrations have also been linked to
ionotropic glutamate receptors, namely N-methyl-D-aspartate (NMDA)
receptors. However, the picture is complex, and both increases and
decreases in NMDA receptor function have been associated with the
ASD phenotype (Gandal et al., 2012).
GABA and glutamate signalling in ASD may also be indirectly de-
railed by mutations in genes coding for proteins that stabilise
GABAergic and glutamatergic synapses. For example, alterations of
neurexin and neuroligin cell adhesion molecules (Ching et al., 2010;
Jamain et al., 2003), postsynaptic density protein 95 (PSD-95) and/or
Shank scaﬀold proteins (Uchino and Waga, 2015; Xing et al., 2016)
confer a high risk for ASD. These molecules anchor pre- and post-sy-
naptic neuron terminals and disruptions of the molecular assembly of
the synapse can potentially cause E-I imbalance (Futai et al., 2007;
Südhof, 2008). Consistent with this, neurexin 1-α (Nrxn1-α) knock-out
mice show a reduction in spontaneous and evoked neurotransmitter
release (Kattenstroth et al., 2004; Missler et al., 2003; Zhang, 2005)
accompanied by behavioural abnormalities that resemble some of the
core ASD symptoms of social impairment and inﬂexibility/stereotypy
(Grayton et al., 2013). Similarly, mice with mutations in the neuroligin
3 gene (Nlgn3) exhibit brain-region speciﬁc synaptic dysfunction (e.g. a
shift of synaptic transmission towards inhibition in the somatosensory
cortex and towards excitation in the hippocampus) and impairments in
social behaviour that mimic ASD (Burrows et al., 2015; Etherton et al.,
2011a, 2011b; Jaramillo et al., 2014; Radyushkin et al., 2009; Tabuchi
et al., 2007). Such “multiple” E-I anomalies, that can be not only brain
region- but even neural circuit-speciﬁc, as shown in multiple animal
models of ASD (Horder et al., 2018; Lee et al., 2017; Nelson and Valakh,
2015) further exemplify the complexities of deﬁning and measuring the
E-I (im)balance in ASD.
Finally, the metabolism of glutamate and GABA is tightly inter-
linked so an alteration in either metabolite may potentially aﬀect the
other. The enzyme glutaminase catalyses the glutamate to glutamine
cycle, allowing glutamine to be stored in astrocytes or converted to
glutamate in both glutamatergic and GABAergic neurons (Rowley et al.,
2012). In excitatory neurons, glutamate is transported into vesicles via
vesicular glutamate transporters, whereas in inhibitory neurons, glu-
tamate is ﬁrst converted to GABA by the glutamic acid decarboxylase
and then transported to vesicles via vesicular GABA transporters. Upon
release, the neurotransmitters are taken up by high aﬃnity membrane
transporters and returned into neurons and surrounding glia, where
they are recycled. Thus, GABA, glutamate and glutamine are in constant
ﬂux. In ASD however, the levels of the multiple enzymes controlling
glutamine-glutamate-GABA cycles are altered (Fatemi et al., 2002;
Shimmura et al., 2013; Yip et al., 2007), and so glutamine-glutamate-
GABA metabolism is likely to be atypical in the ASD brain.
How these diverse E-I anomalies might act mechanistically has been
the subject of a number of recent comprehensive reviews (Foss-Feig
et al., 2017; Gao and Penzes, 2015; Gatto and Broadie, 2010; Lee et al.,
2017; Mullins et al., 2016; Nelson and Valakh, 2015; Uzunova et al.,
2016). For example, Yizhar et al. (2011) have shown that increase of a
cellular E-I balance in the mouse medial prefrontal cortex (mPFC) eli-
cits elevated rhythmic high-frequency (gamma) activity (a disease
correlate in clinical conditions; Orekhova et al., 2007) and social dys-
function. Furthermore, it was recently shown that reducing the E-I ratio
by either reducing the excitability of pyramidal neurons or by in-
creasing the excitability of inhibitory parvalbumin-positive neurons in
the mPFC rescued social deﬁcits in mice lacking the CNTNAP2 gene,
which has been implicated in ASD (Selimbeyoglu et al., 2017). Main-
tenance of E-I balance is thus essential to network function as not only
functional, but also structural properties of neural circuits are deﬁned
by inter-neuronal communication.
3. [1H] Magnetic resonance spectroscopy evidence for E-I
imbalance in ASD
The hypothesis that the glutamine-glutamate-GABA system is al-
tered in ASD has also been addressed by using [1H] magnetic resonance
spectroscopy (MRS) as a non-invasive method to measure tissue levels
of E-I metabolites in the living human brain (Ford and Crewther, 2016;
Schur et al., 2016). In brief, [1H]MRS uses the nuclear magnetic re-
sonance properties of hydrogen atoms to generate a frequency spectrum
(as opposed to the image in MR imaging) (Govindaraju et al., 2000;
Juchem and Rothman, 2014; Stagg et al., 2011) in which diﬀerent
metabolites are identiﬁed by the position of their signal peak, i.e.
chemical shift, along the frequency axis (in units of ‘parts per million’;
ppm). [1H]MRS metabolite levels can then be quantiﬁed by calculating
the area under the corresponding peaks or by ﬁtting the in vivo spectra
to a basis set, i.e. linear combinations of measured or simulated model
spectra of metabolites (Edden et al., 2014; Naressi et al., 2001;
Provencher, 1993). [1H]MRS is not without limitations however. For an
adequate signal-to-noise ratio, standard single voxel [1H]MRS data is
acquired from a predeﬁned and relatively large brain volume-unit
(usually around 4–8 cm3) (Stagg et al., 2011; Zhu and Barker, 2011)
compared with conventional MR image resolution (typically around
1–10mm3) (Blüml, 2013). Therefore, both grey and white matter is
usually sampled within the same voxel. To avoid errors when quanti-
fying metabolites, these so-called ‘partial volume’ eﬀects need to be
corrected by segmenting spectroscopic voxel according to diﬀerent
tissue contents (Dager et al., 2008; Quadrelli et al., 2016). As shown in
Table 1, most of the studies reported using tissue segmentation, how-
ever, exact approaches varied considerably between studies which
might contribute to inconsistencies in the literature. Such partial vo-
lume eﬀects are minimised in [1H]MRS imaging (MRSI), a less fre-
quently used extension of [1H]MRS that allows data from multiple
adjacent small (1 cm3 and below) voxels to be acquired simultaneously
(Blüml, 2013; Oz et al., 2014; Schneider, 2016; Zhu and Barker, 2011).
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However, MRSI is often associated with reduced spectral resolution,
non-uniform water suppression and voxel bleeding artefact (i.e. signal
contamination from neighbouring voxels into the voxel-of-interest),
therefore single voxel [1H]MRS remains the technique of choice
(Astrakas and Argyropoulou, 2016; Blüml, 2013; Duarte et al., 2012;
Jansen et al., 2006).
This large volume also means that [1H]MRS samples tissue meta-
bolites within both neurons and glia and in both intra-and extra-cellular
space (Dager et al., 2008). Therefore, to account for possible variation
in voxel tissue composition, some studies report metabolite con-
centrations as ratios to total creatine (creatine+ phosphocreatine; tCr),
which is assumed to be present at constant concentration in brain tissue
and cerebrospinal ﬂuid (Gussew et al., 2012). However, as an alter-
native to tCr ratios, water has been used as a reference because tCr itself
can be altered in neurodevelopmental conditions (Alger, 2010). Finally,
depending on technical factors, such as the magnetic ﬁeld strength, it is
not always possible to diﬀerentiate between glutamate and glutamine
due to the overlap of their resonant peaks, and the combined signal
termed Glx is commonly reported (Table 1), and thus is only a proxy
measure of glutamate. Similarly, the GABA signal usually also has a
contribution from ‘macromolecules’, and is denoted as GABA+ (Edden
et al., 2012; Henry et al., 2001; Mikkelsen et al., 2017; Near et al.,
2011).
Despite these limitations, [1H]MRS is safe and therefore, in contrast
to other in vivo imaging modalities such as positron emission tomo-
graphy, it can be used repeatedly, and also in children. Indeed, many
[1H]MRS studies of E-I metabolites in ASD have been conducted in
paediatric populations. The initial studies focused on the glutamatergic
system, reporting Glx and glutamate (Glu), with reduced levels found in
the cortical grey matter, frontal lobes, thalamus and cerebellum in
children with ASD (DeVito et al., 2007; Hegarty et al., 2017; Kubas
et al., 2012) (Table 1). However, this was not replicated by others, with
either no diﬀerence in Glx/Glu observed between ASD and control
participants in cortical and subcortical areas (Brix et al., 2015; Cavalho
Pereira et al., 2018; Cochran et al., 2015; Doyle-Thomas et al., 2014;
Drenthen et al., 2016; Friedman et al., 2006; Goji et al., 2017; Harada
et al., 2011; Hardan et al., 2008; Ito et al., 2017; Joshi et al., 2013;
Naaijen et al., 2016) or higher levels reported in ASD – in the anterior
cingulate cortex, frontal lobes, striatum (Bejjani et al., 2012; Doyle-
Thomas et al., 2014; Joshi et al., 2013; Hassan et al., 2013; Naaijen
et al., 2016) and cerebellum (Hassan et al., 2013; Ito et al., 2017)
(Table 1).
By deﬁnition, ASD is a neurodevelopmental condition and how the
brain matures is acknowledged to be quite diﬀerent to even age mat-
ched controls (Amaral et al., 2008; Aoki et al., 2012; Redcay and
Courchesne, 2005). Thus, results of [1H]MRS studies in ASD – as other
MR modalities – may vary depending on the age group sampled. For
example, Corrigan et al. (2013) have reported lower Glx in the cerebral
white matter of 3–4-year-old children; however, there was no change in
Glx when the same children were scanned again at age 6–7 and
9–10 years; and no diﬀerence in grey matter Glx at any age in childhood
(Table 1). However, even in adulthood, when the brain may be ex-
pected to have fully matured, [1H]MRS studies of glutamate have
generated conﬂicting ﬁndings. Lower Glx/Glu has been reported in the
anterior cingulate cortex in ASD adults (Bernardi et al., 2011; Tebartz
van Elst et al., 2014) (Table 1), but others have observed no signiﬁcant
diﬀerence in Glx between ASD adults and controls in this cortical region
(Endres et al., 2017; Libero et al., 2015, 2016) (Table 1). Horder et al.
(2013, 2018) reported lower Glx/Glu in the basal ganglia of adults with
ASD, but unchanged cortical levels (Table 1).
In addition to diﬀerences in study samples and brain regions ex-
amined, diﬀerent [1H]MRS sequences for quantiﬁcation of Glx and/or
Glu have been employed in the studies reviewed here (Table 1). While
conventional [1H]MRS sequences (e.g. STEAM, PRESS) were used by
most, unedited (equivalent to a PRESS) (Horder et al., 2018; Robertson
et al., 2015) as well as the diﬀerence MEGA-PRESS spectra (edit ON-
edit OFF subtraction; please see below) (Ajram et al., 2017; Cavalho
Pereira et al., 2018) were also used to quantify Glx and/or Glu
(Table 1).
In order to sample GABA, customised spectral editing sequences,
such as Meshcher-Garwood Point-resolved spectroscopy (MEGA-PRESS)
carried out at 3 T or higher ﬁeld strengths are required (Mescher et al.,
1998; Mullins et al., 2014). In MEGA-PRESS, a GABA signal can be
resolved from the more prominent Cr+PCr signal at 3 ppm by ap-
plying an editing pulse (edit ON) to the GABA signal at 1.9 ppm in-
terleaved with edit OFF pulse (no frequency-selective editing pulses
applied, or if applied, at a diﬀerent frequency) (Cleve et al., 2015; Long
et al., 2015; Maddock et al., 2016; Mescher et al., 1998; Mullins et al.,
2014; Shungu et al., 2016). The application of this editing pulse results
in the co-editing of other molecules present in the ﬁnal spectrum,
namely the Glx at 3.75 ppm and ‘macromolecules’ at 3 ppm (Cleve
et al., 2015; O'Gorman et al., 2011). Thus, the GABA signal at 3 ppm is
commonly reported as GABA+ (Table 1). Furthermore, due to low
tissue concentration of GABA, MEGA-PRESS requires larger ROI vo-
lumes (typically around 27 cm3) and longer acquisition times ideally
between 7 and 10min (Mikkelsen et al., 2018). This was generally
applied in all but two reviewed study (Kirovski et al., 2018; Kubas et al.,
2012) (Table 1). In ASD, most studies of [1H]MRS GABA+ have been
conducted only in the last four years (Table 1). The majority have re-
cruited children (Brix et al., 2015; Cavalho Pereira et al., 2018; Cochran
et al., 2015; Drenthen et al., 2016; Gaetz et al., 2014; Goji et al., 2017;
Harada et al., 2011; Ito et al., 2017; Kubas et al., 2012; Puts et al., 2017;
Rojas et al., 2014), with three studies involving only adults (Ajram
et al., 2017; Horder et al., 2018; Kirovski et al., 2018; Robertson et al.,
2015), and one combining children and adults (Port et al., 2017). The
pattern of GABA+ diﬀerences in ASD compared to typically developing
controls is a little more consistent than for Glx and Glu, with either
lower measures or no diﬀerence in regional GABA+ reported. Thus,
lower GABA+ has been found in the motor, auditory and frontal cor-
tices and in the sensorimotor regions, anterior cingulate cortex and
cerebellum (Gaetz et al., 2014; Harada et al., 2011; Ito et al., 2017;
Kubas et al., 2012; Port et al., 2017; Puts et al., 2017; Rojas et al.,
2014), whereas others have observed no diﬀerences in GABA+ in the
prefrontal and occipital cortices (Ajram et al., 2017; Brix et al., 2015;
Cavalho Pereira et al., 2018; Cochran et al., 2015; Drenthen et al.,
2016; Gaetz et al., 2014; Goji et al., 2017; Horder et al., 2018; Puts
et al., 2017; Robertson et al., 2015), lenticular nuclei (Harada et al.,
2011), motor cortex (Robertson et al., 2015), superior temporal sulcus
(Kirovski et al., 2018), basal ganglia (Horder et al., 2018) and cere-
bellum (Goji et al., 2017) (Table 1).
Reduction in GABA in the somatosensory cortex has been associated
with altered tactile function in children with ASD (Puts et al., 2017).
Interestingly, developmental tactile perception abnormalities due to a
loss of presynaptic inhibition of somatosensory neuron transmission
have been shown to result in ASD-related social interaction deﬁcits in
mice (Oreﬁce et al., 2016). However, even in the absence of group
diﬀerences in GABA+, a role for GABA in ASD has still been argued
based on ﬁndings that [1H]MRS GABA+ levels in ASD are inversely
correlated with scores on the Autism Spectrum Screening Questionnaire
(Brix et al., 2015) and with the communication and delayed develop-
ment scores of the Autism Diagnostic Interview – Revised (Cavalho
Pereira et al., 2018). More diﬃcult to disentangle are the results from
Robertson et al. (2015). In their study, occipital GABA+measures were
equivalent in ASD and control groups, but the ASD group had a deﬁcit
in the performance of a binocular rivalry test of visual function thought
to rely upon visual cortical E-I balance. The authors went on to show
that a positive correlation between GABA+ and performance on a bi-
nocular rivalry task in control group was not evident in the ASD group,
and suggested that the results supported an impairment in ‘inhibitory
signalling’ in ASD (Robertson et al., 2015). This may well be the case,
but because [1H]MRS captures the metabolites within a composite of
cell types and does not capture active neurotransmission, it is
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impossible to say with certainty.
4. E-I ﬂux in ASD
One perspective on this constellation of [1H]MRS ﬁndings in ASD, is
that their range may mirror the etiological and phenotypical hetero-
geneity of the spectrum as well as the variety in the typically devel-
oping control groups used for comparison. For example, [1H]MRS
measures of glutamate and GABA+ diﬀer even within the typically
developing population (Bogner et al., 2010; Brix et al., 2017; Kaiser
et al., 2005; O'Gorman et al., 2011; Sailasuta et al., 2008).
Another consideration for the ﬁeld is that, in the main, indices of
glutamate and GABA have been assessed separately in ASD; yet the
results have been interpreted in terms of E-I balance (Dickinson et al.,
2016). It could be argued that a true imbalance can only be uncovered
if the level of each metabolite is reported. Thus, if a GABA decrease is
accompanied by a glutamate decrease, then the system may remain
balanced. Moreover, until recently, the logic of trying to capture me-
tabolites within a glutamine-glutamate-GABA cycle that is constantly
changing or in ‘ﬂux’ in cohorts with and without ASD, has not been
questioned. We now suggest that replication diﬃculties in cross-sec-
tional studies of glutamate and GABA pathways in ASD arise, at least in
part, because they sample only one part of an E-I system, which is a
‘moving target’. As described earlier, the regulatory enzymes control-
ling this dynamic system are altered in ASD, and so E-I ﬂux in ASD is
therefore very likely to be atypical.
Supporting this hypothesis, there is now evidence that [1H]MRS is
sensitive to changes in E-I ﬂux elicited by pharmacological probes that
challenge the system. This comes initially from studies in rats, which
have established that [1H]MRS can reliably capture changes in gluta-
mate and GABA levels following pharmacological interventions
(Waschkies et al., 2014). Speciﬁcally, [1H]MRS was used to track the E-
I response to pharmacologically relevant doses of compounds with a
known mechanism of action on GABAergic and glutamatergic neuro-
transmission, namely vigabatrin, 3-mercaptopropionate, tiagabine,
methionine sulfoximine, and riluzole. Clear drug dose-[1H]MRS eﬀect
relationships were demonstrated, with changes as low as 6% in gluta-
mate and 12% in GABA reliably measured using [1H]MRS. The authors
concluded that quantitative [1H]MRS of glutamate and GABA may
usefully reveal E-I ‘target engagement’ – in other words, the interaction
of a drug with its biological goal (Waschkies et al., 2014). We have
recently extended this approach to humans. Using [1H]MRS, we found
that the anti-glutamate and pro-GABA drug riluzole increased the
proportion of GABA+ relative to the total level of GABA+ and Glx
metabolites in the prefrontal cortex in ASD, but decreased it in controls,
despite a comparable baseline between groups (Ajram et al., 2017).
This diﬀerence in E-I ‘responsivity’ in ASD has important implica-
tions for the development of pharmacological treatments for ASD, as it
suggests that drugs may not act in the ASD brain the same way as in the
typically developing brain. That is, selecting a compound for a trial/
treatment in ASD based on its mechanism of action in the typical brain
may not always be appropriate. Moreover, the response to pharmaco-
logical treatments in ASD may itself be heterogeneous. This may, for
instance, explain why some – but not all – individuals with ASD can
have paradoxical responses to GABAA/benzodiazepine receptor ago-
nists; usually these medications have a sedative eﬀect, but ‘excitation’
has at times been reported in individuals with ASD (Lemonnier et al.,
2012; Marrosu et al., 1987). It may also explain some of the trial dis-
appointments in ASD. For example, lamotrigine, an anticonvulsant, was
proposed to be a potential treatment for ASD because it inhibits sy-
naptic glutamate release in excitatory neurons. Unfortunately, it did not
improve clinical outcomes in children with ASD (Belsito et al., 2001). A
similar failure followed the use of D-cycloserine, a partial agonist at the
NMDA glutamate receptor (Belsito et al., 2001; Minshawi et al., 2016;
Posey et al., 2004).
5. Conclusions
We conclude that disruption within E-I systems could serve as a
biomarker for ASD. However, we extend this observation to suggest that
E-I systems in the ASD brain are pharmacologically atypical. However,
the picture is far from straight-forward. This means that we need better
strategies, potentially including [1H]MRS, to examine the biological
response or target engagement to proposed treatments in sub-groups of
individuals with ASD. The identiﬁcation of more pharmacologically
homogeneous sub-groups within the spectrum may inform a new gen-
eration of biologically-driven clinical trials and avoid the time and
expense (and failure) of un-stratiﬁed large-scale studies.
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